<h1 id="hyperkalemia">Hyperkalemia</h1>
<p><strong>Potassium regulation</strong></p>
<ul>
<li><strong>Internal K shift:</strong> modulated by insulin, catecholamines, acid-base status</li>
<li><strong>Total body K elimination:</strong> By kidney(95%) and gut (5%)</li>
</ul>
<h2 id="adverse-effects-of-hyperkalemia">Adverse effects of hyperkalemia</h2>
<ul>
<li><strong>Cardiac:</strong> Peaked T, wide QRS, loss of P wave, sine wave; although V fib may be first cardiac manifestation.</li>
<li><strong>Neuromuscular:</strong> Paresthesias,weakness</li>
<li><strong>Metabolic:</strong> Mild hyperchloremic metabolic acidosis</li>
</ul>
<h2 id="treatment-of-hyperkalemia">Treatment of hyperkalemia</h2>
<p><strong>Cardiac membrane stabilization </strong></p>
<ul>
<li><strong>Calcium:</strong> Reduces threshold potential in myocytes; check to be sure not on digoxin</li>
<li><p><strong>Hypertonic saline:</strong> Only for severe hyponatremia in setting of hyperkalemia</p>
<p><strong>K redistribution</strong></p>
</li>
<li><strong>Insulin:</strong> Drives K intracellularly and drops serum K level by 0.6 mmol/L</li>
<li><strong>Beta-agonist:</strong> Drives K intracellularly and 10 mg albuterol drops serum K level by 0.6 mmol/L(20 mg --&gt; K drops by 1 mmol/L);effective in only 60% of patients</li>
</ul>
<p><strong> K elimination via kidney/gut</strong></p>
<ul>
<li><strong>Bicarbonate:</strong> drives K out at distal nephron; best as infusion x 4-6 hrs</li>
<li><strong>Loop diuretic</strong></li>
<li><strong>Exchange resin</strong> (sodium polystyrene sulfonate): case reports of colonic necrosis;constipating med and so combined with sorbitol; minimal benefit. </li>
</ul>
<table>
  <tr>
    <th>Agent</th>
    <th>Dose</th>
    <th>Onset</th>
    <th>Duration</th>
    <th>Complication</th>
  </tr>
  <tr>
    <td colspan="5"><strong>Membrane Stabilization</strong></td>
  </tr>
  <tr>
    <td><span class="drug">Ca gluconate 10%</span></td>
    <td>10 mL over 10 min</td>
    <td>immediate</td>
    <td>30-60min</td>
    <td>hypercalcemia</td>
  </tr>
  <tr>
    <td><span class="drug">Hypertonic 3% NaCl</span></td>
    <td>50cc IV push</td>
    <td>immediate</td>
    <td>unknown</td>
    <td>volume overload, hypertonicity</td>
  </tr>
  <tr>
    <td colspan="5"><strong>Redistribution</strong></td>
  </tr>
  <tr>
    <td><span class="drug">Insulin</span></td>
    <td>10 units IVP with D50W</td>
    <td>20 min</td>
    <td>4-6 hr</td>
    <td>hypoglycemia</td>
  </tr>
  <tr>
    <td><span class="drug">Albuterol nebulized</span></td>
    <td>20mg/4cc over 10 min</td>
    <td>30 min</td>
    <td>2 hrs</td>
    <td>tachycardia</td>
  </tr>
  <tr>
    <td colspan="5"><strong>Elimination</strong></td>
  </tr>
  <tr>
    <td><span class="drug">Loop diuretic</span></td>
    <td>furosemide 40-80 mg IV</td>
    <td>15 min</td>
    <td>2-3 hr</td>
    <td>volume depletion</td>
  </tr>
  <tr>
    <td><span class="drug">Sodium bicarbonate</span></td>
    <td>150 mmol/L IV</td>
    <td>hours</td>
    <td>infusion</td>
    <td>metabolic alkalosis, volume overload</td>
  </tr>
  <tr>
    <td><span class="drug">Kayexalate</span></td>
    <td>150-30 g</td>
    <td>&gt;2 hrs</td>
    <td>4-6 hr</td>
    <td>variable efficacy</td>
  </tr>
  <tr>
    <td><span class="drug">Hemodialysis</span></td>
    <td></td>
    <td>immediate</td>
    <td>3 hrs</td>
    <td>arrhythmias</td>
  </tr>
</table>


<h2 id="references">References</h2>
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18936701">Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008; 36:3246-51.</a></li>
</ul>
